NZ Colorectal Oncology Research Review Issue 32

In this issue:
  -  MEK/MDM2 inhibition and antitumor efficacy
  -  Faecal immunochemical test for CRC
  -  Clinical and molecular profile of early-onset CRC
  -  mFOLFOXIRI vs mFOLFOX6 in locally advanced rectal cancer
  -  Doublet + anti-EGFR vs triplet + bevacizumab for mCRC
  -  Long-term survival with regorafenib
  -  Regorafenib + fruquintinib in mCRC
  -  PD-1 blockade, chemotherapy and immunoradiotherapy for anal SCC
  -  Cytokine-induced killer cell immunotherapy for CRC patients
  -  FOLFIRI vs single-agent irinotecan for second-line mCRC

Please login below to download this issue (PDF)